BGB-21447

N/A

Report date: 2025/01/06 16:48:12
NME

Base Information

Drug NameBGB-21447
Drug Alias NameBGB-21447
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsMetastatic breast cancerRichter's SyndromeBreast Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeigene (Suzhou) Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBeOne Medicines LtdBeigene (Suzhou) Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerRichter's SyndromeBreast Neoplasms +[8] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A